Quarterly report · Q2
4320.TEDINET S100TDO6
Period2023-10-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.1bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥13.6bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.3bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥741m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥840m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥744m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥838m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥744m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥861m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥372m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥688m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥495m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥405m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥536m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥12.9bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥11.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥11.2bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.1bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥451m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥796m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥289m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥353m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥862m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥254m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.0bn | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥755m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥194m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥24.77 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.68 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.91 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.99 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.5 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥25m |
| jpcrp040300-q2r_E05233-000Heathcare Solution Businessreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥7.9bn |
| jpcrp040300-q2r_E05233-000Heathcare Solution Businessreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥7.9bn |
| jpcrp040300-q2r_E05233-000Heathcare Solution Businessreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥798m |
| jpcrp040300-q2r_E05233-000Marketing Solution Businessreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥202m |
| jpcrp040300-q2r_E05233-000Marketing Solution Businessreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥202m |
| jpcrp040300-q2r_E05233-000Marketing Solution Businessreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥32m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥8.1bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥8.1bn |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥766m |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-03-31 | −¥26m |
| jpcrp040300-q2r_E05233-000Heathcare Solution Businessreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| jpcrp040300-q2r_E05233-000Heathcare Solution Businessreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥7.1bn |
| jpcrp040300-q2r_E05233-000Heathcare Solution Businessreportable segment | segment profit | 2022-10-01 → 2023-03-31 | ¥873m |
| jpcrp040300-q2r_E05233-000Marketing Solution Businessreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥240m |
| jpcrp040300-q2r_E05233-000Marketing Solution Businessreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥240m |
| jpcrp040300-q2r_E05233-000Marketing Solution Businessreportable segment | segment profit | 2022-10-01 → 2023-03-31 | −¥8m |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥7.3bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥7.3bn |
| —segment total | segment profit | 2022-10-01 → 2023-03-31 | ¥865m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 482
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -297555000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -381324000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -5000000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -99963000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -30000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -894000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -735000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration | 39050000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration | 37331000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | CurrentYTDDuration | 3750000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | 66000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -180407000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -208788000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | -39200000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -70070000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -193970000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 1046132000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -736958000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 241528000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3958521000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3138112000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3221562000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 3379641000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 402816000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 446506000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 8552000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 12632000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 5037000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | -1382000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 98217000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 13433000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 4198000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 1581000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05233-000HeathcareSolutionBusinessReportableSegmentsMember | 7101473000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05233-000MarketingSolutionBusinessReportableSegmentsMember | 239868000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 7341341000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 7341341000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05233-000HeathcareSolutionBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05233-000MarketingSolutionBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05233-000HeathcareSolutionBusinessReportableSegmentsMember | 7101473000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05233-000MarketingSolutionBusinessReportableSegmentsMember | 239868000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 7341341000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |